We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study
Read MoreHide Full Article
Key Takeaways
Nektar's phase IIb REZOLVE-AD study met primary and key secondary endpoints in eczema treatment.
All rezpeg doses showed significant EASI and body surface area improvements at week 16.
Nektar shares surged 156.3% after the news and gained an additional 6.8% in after-market trading.
Nektar Therapeutics (NKTR - Free Report) announced that the phase IIb REZOLVE-AD study evaluating its lead pipeline candidate, rezpegaldesleukin (rezpeg), in patients with moderate-to-severe atopic dermatitis, met its primary and key secondary endpoints.
The REZOLVE-AD study evaluated three doses of subcutaneous rezpeg (24 µg/kg, 18 µg/kg and 24 µg/kg) in patients with moderate-to-severe atopic dermatitis, also known as eczema.
The study met its primary endpoint of mean improvement in Eczema Area and Severity Score (EASI) from baseline for all three doses of rezpeg as compared to placebo at week 16.
Shares of the company surged 156.3% on Tuesday following the announcement of the news. The stock continued to gain another 6.8% in the after-market hours.
Year to date, shares of Nektar have rallied 75.3% against the industry’s decrease of 0.1%.
Image Source: Zacks Investment Research
More on NKTR's REZOLVE-AD Study on Rezpeg
Data from the REZOLVE-AD study showed that treatment with all three doses of rezpeg led to a statistically significant improvement for the key secondary endpoints of EASI-75 (which indicates the percentage of patients with at least a 75% reduction in EASI from baseline), EASI-50 and the mean improvement in Body Surface Area score at week 16.
Additionally, treatment with the highest dose of rezpeg at week 16 led to a statistical significance on EASI-90, i.e., the percentage of patients reaching at least a 90% reduction in their EASI scores.
The safety profile of rezpeg during the 16-week induction period was similar to that observed in previously reported data.
The company plans to present the 16-week induction phase data from the REZOLVE-AD study at a medical conference later in 2025.
Per management, the rapid reduction in EASI scores and significant itch improvement highlight the potential of rezpeg to become a first and best-in-class immune-modulator for the treatment of inflammatory skin disorders like atopic dermatitis and other autoimmune conditions.
Rezpeg selectively activates regulatory T-cells (Tregs) to calm the immune system and reduce inflammation. Unlike older IL-2 therapies that broadly stimulate both protective and aggressive immune cells, rezpeg specifically expands Tregs without harmful immune activation. This targeted approach makes it safer for treating autoimmune and inflammatory diseases.
NKTR Also Studying Rezpeg for Alopecia Areata
Rezpeg is being developed as a self-administered injection for several autoimmune and inflammatory diseases.
Besides atopic dermatitis, the company is also investigating rezpeg in the phase IIb REZOLVE-AA study for treating patients with severe-to-very severe alopecia areata.
Enrollment in the REZOLVE-AA study was completed in February, with top-line data from the same expected in the fourth quarter of 2025.
It can be inferred that data from the REZOLVE-AD study has exceeded investors' expectations. As a result, investors are now looking forward to the data from the REZOLVE-AA study on rezpeg, which, if positive, can become a huge catalyst for the NKTR stock.
We note that Nektar regained full rights to rezpeg from pharma giant Eli Lilly (LLY - Free Report) in April 2023 and took charge of its clinical development.
Rezpeg was earlier developed in collaboration with Lilly for several autoimmune indications.
Rezpeg is now a wholly owned asset of Nektar, and the company owes no royalty payments to LLY.
In the past 60 days, estimates for Exelixis’ earnings per share have increased from $2.31 to $2.61 for 2025. During the same time, earnings per share estimates for 2026 have increased from $2.83 to $3.03. Year to date, shares of EXEL have increased 37.7%.
EXEL’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 48.60%.
In the past 60 days, estimates for Puma Biotechnology’s earnings per share have increased from 60 cents to 65 cents for 2025. During the same time, earnings per share estimates for 2026 have risen from 46 cents to 51 cents. Year to date, shares of PBYI have gained 10.2%.
PBYI’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 171.43%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study
Key Takeaways
Nektar Therapeutics (NKTR - Free Report) announced that the phase IIb REZOLVE-AD study evaluating its lead pipeline candidate, rezpegaldesleukin (rezpeg), in patients with moderate-to-severe atopic dermatitis, met its primary and key secondary endpoints.
The REZOLVE-AD study evaluated three doses of subcutaneous rezpeg (24 µg/kg, 18 µg/kg and 24 µg/kg) in patients with moderate-to-severe atopic dermatitis, also known as eczema.
The study met its primary endpoint of mean improvement in Eczema Area and Severity Score (EASI) from baseline for all three doses of rezpeg as compared to placebo at week 16.
Shares of the company surged 156.3% on Tuesday following the announcement of the news. The stock continued to gain another 6.8% in the after-market hours.
Year to date, shares of Nektar have rallied 75.3% against the industry’s decrease of 0.1%.
Image Source: Zacks Investment Research
More on NKTR's REZOLVE-AD Study on Rezpeg
Data from the REZOLVE-AD study showed that treatment with all three doses of rezpeg led to a statistically significant improvement for the key secondary endpoints of EASI-75 (which indicates the percentage of patients with at least a 75% reduction in EASI from baseline), EASI-50 and the mean improvement in Body Surface Area score at week 16.
Additionally, treatment with the highest dose of rezpeg at week 16 led to a statistical significance on EASI-90, i.e., the percentage of patients reaching at least a 90% reduction in their EASI scores.
The safety profile of rezpeg during the 16-week induction period was similar to that observed in previously reported data.
The company plans to present the 16-week induction phase data from the REZOLVE-AD study at a medical conference later in 2025.
Per management, the rapid reduction in EASI scores and significant itch improvement highlight the potential of rezpeg to become a first and best-in-class immune-modulator for the treatment of inflammatory skin disorders like atopic dermatitis and other autoimmune conditions.
Rezpeg selectively activates regulatory T-cells (Tregs) to calm the immune system and reduce inflammation. Unlike older IL-2 therapies that broadly stimulate both protective and aggressive immune cells, rezpeg specifically expands Tregs without harmful immune activation. This targeted approach makes it safer for treating autoimmune and inflammatory diseases.
NKTR Also Studying Rezpeg for Alopecia Areata
Rezpeg is being developed as a self-administered injection for several autoimmune and inflammatory diseases.
Besides atopic dermatitis, the company is also investigating rezpeg in the phase IIb REZOLVE-AA study for treating patients with severe-to-very severe alopecia areata.
Enrollment in the REZOLVE-AA study was completed in February, with top-line data from the same expected in the fourth quarter of 2025.
It can be inferred that data from the REZOLVE-AD study has exceeded investors' expectations. As a result, investors are now looking forward to the data from the REZOLVE-AA study on rezpeg, which, if positive, can become a huge catalyst for the NKTR stock.
We note that Nektar regained full rights to rezpeg from pharma giant Eli Lilly (LLY - Free Report) in April 2023 and took charge of its clinical development.
Rezpeg was earlier developed in collaboration with Lilly for several autoimmune indications.
Rezpeg is now a wholly owned asset of Nektar, and the company owes no royalty payments to LLY.
Nektar Therapeutics Price
Nektar Therapeutics price | Nektar Therapeutics Quote
NKTR's Zacks Rank & Stocks to Consider
Nektar currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Exelixis (EXEL - Free Report) and Puma Biotechnology (PBYI - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Exelixis’ earnings per share have increased from $2.31 to $2.61 for 2025. During the same time, earnings per share estimates for 2026 have increased from $2.83 to $3.03. Year to date, shares of EXEL have increased 37.7%.
EXEL’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 48.60%.
In the past 60 days, estimates for Puma Biotechnology’s earnings per share have increased from 60 cents to 65 cents for 2025. During the same time, earnings per share estimates for 2026 have risen from 46 cents to 51 cents. Year to date, shares of PBYI have gained 10.2%.
PBYI’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 171.43%.